TB-500

Quick Facts

Introduction

TB-500 is a synthetic peptide closely related to thymosin beta-4 (Tβ4), a naturally occurring protein found in nearly all cell types and present at high concentrations in wound fluid. In the research literature it is studied chiefly as a model compound for cell migration and soft-tissue repair, and it is frequently examined alongside BPC-157 because the two are associated with complementary repair mechanisms.

It is important to separate TB-500 from its parent molecule. Thymosin beta-4 is a 43-amino-acid protein with a well-characterized biology; TB-500 is generally described as a synthetic construct corresponding to the actin-binding region of that protein, the stretch most associated with its cytoskeletal activity. Much of the preclinical reasoning about TB-500 is therefore extrapolated from the broader Tβ4 literature, a nuance researchers keep in view when interpreting results.

This profile covers what TB-500 is, its relationship to thymosin beta-4, the actin-regulation mechanism most associated with it, the repair and migration research domains it appears in, and how it compares with related compounds such as BPC-157 and GHK-Cu. Related compounds are catalogued in the peptide database.

What is TB-500?

TB-500 is a synthetic peptide built around the active, actin-binding portion of thymosin beta-4. Where the full Tβ4 protein carries out several functions, TB-500 is designed to concentrate on the sequence most associated with G-actin binding — the interaction researchers most often invoke to explain its reported effects on cell motility and tissue organization.

Because it is a comparatively short, water-soluble fragment, TB-500 is practical to handle in a laboratory setting: it dissolves readily and is straightforward to reconstitute. Researchers nonetheless emphasize that, as with most peptides in this category, its human pharmacology is not well characterized, and the bulk of supporting data comes from animal and cell-culture systems.

Molecular and structural characteristics

Thymosin beta-4 is a 43-residue protein, and TB-500 corresponds to the central actin-binding domain that gives the parent molecule much of its cytoskeletal activity. The fragment is small, hydrophilic, and lacks disulfide bonds, which is consistent with its easy solubility and the simplicity of its handling relative to larger, more delicate peptides.

Mechanism of action

The mechanism most associated with TB-500 is actin regulation. Thymosin beta-4 is one of the main intracellular sequesterers of G-actin (the monomeric form of actin), and by buffering the pool of available actin monomers it influences how quickly cells can build and remodel the cytoskeleton. Because cell migration depends on rapid, directional cytoskeletal remodeling, this actin-binding activity is the leading explanation for the migration effects reported in repair models.

Beyond actin, the broader Tβ4 literature associates the molecule with angiogenesis — the formation of new blood vessels — and with anti-inflammatory and matrix-remodeling effects. These are studied as part of an integrated repair program: cells must migrate into a wound, new vasculature must supply it, and the surrounding matrix must be reorganized. TB-500 is examined as a tool for probing these overlapping processes.

A key interpretive point is that TB-500's mechanism is inferred largely from its parent protein. When researchers describe its actin-binding or angiogenic activity, they are typically reasoning from thymosin beta-4 biology and confirming where the fragment behaves similarly. This makes the mechanism plausible and well-motivated, but also means that fragment-specific data are thinner than the parent-molecule data they are built on.

• G-actin sequestration and cytoskeletal regulation (primary association).
• Promotion of directional cell migration in repair models.
• Angiogenesis, inherited from the broader Tβ4 literature.
• Anti-inflammatory and extracellular-matrix remodeling effects.

Repair and cell-migration research

The dominant research context for TB-500 is soft-tissue repair, where investigators examine its association with faster cell migration into injured areas and with markers of tissue reorganization. Muscle, tendon, and dermal models appear frequently, reflecting the cytoskeletal theme: tissues that heal through coordinated cell movement are the natural setting for an actin-regulating compound.

A second strand of work, again inherited from thymosin beta-4, examines cardiac and vascular models, where Tβ4 has been studied for cell survival and vessel formation after injury. These endpoints are why TB-500 is sometimes grouped with angiogenesis-focused peptides even though its headline mechanism is cytoskeletal rather than directly vascular.

Comparison: TB-500 vs BPC-157 vs GHK-Cu

TB-500 is most often compared with BPC-157, with which it shares the broad theme of soft-tissue repair, and with GHK-Cu, a copper-binding tripeptide studied for matrix remodeling. The three overlap in the idea of supporting repair but diverge in their proposed mechanisms.

Researchers sometimes study BPC-157 and TB-500 together precisely because their proposed mechanisms are complementary — angiogenesis and growth-factor signaling on one side, actin-driven migration on the other. Full entries for each are in the peptide database.

Half-life and pharmacokinetic considerations

Public pharmacokinetic data specific to TB-500 are limited, and much of what is cited is reasoned from thymosin beta-4. One reason the fragment is studied at all is the expectation that a smaller, defined construct may distribute differently from the full 43-residue protein, but rigorous human absorption, distribution, and clearance data are not well established.

Half-life estimates should be treated as preliminary research observations. Because so much TB-500 reasoning is borrowed from its parent molecule, researchers are careful to distinguish fragment-specific measurements from parent-protein extrapolations when interpreting any pharmacokinetic claim.

This data gap shapes interpretation. Without well-characterized fragment-specific pharmacokinetics, the concentrations used in animal and cell-culture studies cannot be confidently related to other systems, and findings should stay anchored to the specific models that produced them.

Reconstitution and handling considerations

TB-500 is readily soluble in sterile or bacteriostatic water. Diluent is added slowly down the vial wall and the vial is swirled gently rather than shaken, to avoid foaming or shear damage. The reconstituted solution should be clear; cloudiness or particulates indicate it should be discarded.

Working concentration is chosen so that research volumes are convenient and reproducible. The reconstitution calculator and reconstitution guide describe the general method used across the peptides in this library.

• Add diluent slowly; swirl gently rather than shaking.
• Confirm the solution is clear before use.
• Choose a working concentration that keeps research volumes reproducible.
• Protect from light and excess warmth.

Storage considerations

Lyophilized TB-500 is most stable frozen at −20 °C, away from light and moisture. Once reconstituted, it is refrigerated at 2–8 °C and used within a limited window, avoiding repeated freeze–thaw cycles. Aliquoting reduces how often a given solution is cycled.

Research limitations

TB-500 is an unapproved research compound, and much of its evidence is either preclinical or extrapolated from thymosin beta-4. Human pharmacokinetic and safety data are limited, and fragment-specific data are thinner than the parent-protein literature they draw on. Reported effects are model- and concentration-dependent and are described here strictly for research reference.

• Evidence base is predominantly preclinical and partly extrapolated from Tβ4.
• Human pharmacokinetic and safety data are limited.
• Fragment-specific data are thinner than parent-protein data.
• It is not an approved therapy and is described solely for research reference.

Frequently Asked Questions

Related Research Profiles

References

1. Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005.Source
2. Crockford D, et al. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci. 2010.Source